KA-2887-LD38 / KYinno, Escugen Biotechnology - LARVOL DELTA

KA-2887-LD38: a novel bispecific antibody-drug conjugate (ADC) targeting both EGFR and PD-L1 (AACR 2025) - "Toxicity studies on KA-2887-LD38 are ongoing. The results suggest that KA-2887-LD38 holds significant potential for the treatment of a variety of solid tumors."

IO biomarker • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • EGFR